Article written by Gary Finnegan. Chronic kidney disease affects approximately 700 million people worldwide with many going on to require dialysis. Now a new enzyme has been discovered… read more.
GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.
Health Canada has approved daratumumab injection (Darzalex SC), a subcutaneous formulation of daratumumab (Darzalex), for use in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd; VCd) in the treatment… read more.
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.
There is no excerpt because this is a protected post.
Cycling at moderate intensity during dialysis could drastically improve the heart health of patients with kidney failure and result in significant savings for the NHS, according to new… read more.
FibroGen, Inc. has provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase III program for the treatment of anemia of chronic… read more.
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.
GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for… read more.
AstraZeneca and FibroGen, Inc. announced that the FDA informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new… read more.
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of… read more.
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
